Shares of Tenax Therapeutics Inc (NASDAQ:TENX) rose 6.4% during mid-day trading on Monday . The company traded as high as $1.26 and last traded at $1.33. Approximately 5,200 shares changed hands during trading, a decline of 99% from the average daily volume of 557,567 shares. The stock had previously closed at $1.25.
Separately, ValuEngine upgraded shares of Tenax Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, November 7th.
A hedge fund recently raised its stake in Tenax Therapeutics stock. Renaissance Technologies LLC lifted its stake in shares of Tenax Therapeutics Inc (NASDAQ:TENX) by 45.8% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 83,400 shares of the specialty pharmaceutical company’s stock after buying an additional 26,200 shares during the quarter. Renaissance Technologies LLC owned about 5.75% of Tenax Therapeutics worth $526,000 as of its most recent SEC filing. Institutional investors own 12.09% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Tenax Therapeutics (TENX) Stock Price Up 6.4%” was reported by Equities Focus and is owned by of Equities Focus. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.equitiesfocus.com/2019/02/06/tenax-therapeutics-tenx-stock-price-up-6-4.html.
Tenax Therapeutics Company Profile (NASDAQ:TENX)
Tenax Therapeutics, Inc, a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome.
Recommended Story: How analysts view the yield curve
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.